BRPI0413427A - derivados de piridilpirrol ativos como inibidores da cinase - Google Patents
derivados de piridilpirrol ativos como inibidores da cinaseInfo
- Publication number
- BRPI0413427A BRPI0413427A BRPI0413427-3A BRPI0413427A BRPI0413427A BR PI0413427 A BRPI0413427 A BR PI0413427A BR PI0413427 A BRPI0413427 A BR PI0413427A BR PI0413427 A BRPI0413427 A BR PI0413427A
- Authority
- BR
- Brazil
- Prior art keywords
- active
- kinase inhibitors
- pyridylpyrrole
- derivatives
- pyridylpyrrole derivatives
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Abstract
"DERIVADOS DE PIRIDILPIRROL ATIVOS COMO INIBIDORES DA CINASE". Apresente invenção refere-se a derivados de piridilpirrol de fórmula (I) e sais farmaceuticamente aceitáveis destes, como definido no relatório descritivo, e composições farmacêuticas compreendendo-os; os compostos da invenção podem ser úteis, em terapia, no tratamento de doenças associadas com uma atividade de proteína cinase desregulada, como o câncer.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US49407603P | 2003-08-08 | 2003-08-08 | |
US58083604P | 2004-06-18 | 2004-06-18 | |
PCT/EP2004/008811 WO2005013986A1 (en) | 2003-08-08 | 2004-08-06 | Pyridylpyrrole derivatives active as kinase inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
BRPI0413427A true BRPI0413427A (pt) | 2006-10-10 |
Family
ID=34138800
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI0413427-3A BRPI0413427A (pt) | 2003-08-08 | 2004-08-06 | derivados de piridilpirrol ativos como inibidores da cinase |
Country Status (10)
Country | Link |
---|---|
US (1) | US20050043346A1 (pt) |
EP (1) | EP1660085B1 (pt) |
JP (1) | JP2007501825A (pt) |
AT (1) | ATE411022T1 (pt) |
BR (1) | BRPI0413427A (pt) |
CA (1) | CA2535125A1 (pt) |
DE (1) | DE602004017194D1 (pt) |
ES (1) | ES2313051T3 (pt) |
MX (1) | MXPA06001557A (pt) |
WO (1) | WO2005013986A1 (pt) |
Families Citing this family (50)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7572914B2 (en) * | 2003-12-19 | 2009-08-11 | Takeda Pharmaceutical Company Limited | Kinase inhibitors |
WO2005105788A1 (en) * | 2004-04-23 | 2005-11-10 | Takeda San Diego, Inc. | Indole derivatives and use thereof as kinase inhibitors |
WO2006023931A2 (en) * | 2004-08-18 | 2006-03-02 | Takeda San Diego, Inc. | Kinase inhibitors |
US7713973B2 (en) * | 2004-10-15 | 2010-05-11 | Takeda Pharmaceutical Company Limited | Kinase inhibitors |
CA2609126A1 (en) | 2005-05-20 | 2006-11-30 | Vertex Pharmaceuticals Incorporated | Pyrrolopyridines useful as inhibitors of protein kinase |
EP2270014A1 (en) | 2005-09-22 | 2011-01-05 | Incyte Corporation | Azepine inhibitors of janus kinases |
US8119655B2 (en) * | 2005-10-07 | 2012-02-21 | Takeda Pharmaceutical Company Limited | Kinase inhibitors |
WO2007070514A1 (en) * | 2005-12-13 | 2007-06-21 | Incyte Corporation | Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as janus kinase inhibitors |
AU2015201850B2 (en) * | 2005-12-13 | 2017-03-02 | Incyte Holdings Corporation | Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors |
US20070142414A1 (en) * | 2005-12-16 | 2007-06-21 | Pharmacia Italia S.P.A. | N-substituted pyrrolopyridinones active as kinase inhibitors |
US7618982B2 (en) | 2005-12-19 | 2009-11-17 | Nerviano Medical Sciences S.R.L. | Heteroarylpyrrolopyridinones active as kinase inhibitors |
WO2007096334A1 (en) * | 2006-02-24 | 2007-08-30 | Pfizer Italia Srl | Pyrrolopyrrolones active as kinase inhibitors |
EP2223925A1 (en) * | 2006-10-09 | 2010-09-01 | Takeda Pharmaceutical Company Limited | Kinase inhibitors |
GEP20135728B (en) | 2006-10-09 | 2013-01-25 | Takeda Pharmaceuticals Co | Kinase inhibitors |
US8513270B2 (en) | 2006-12-22 | 2013-08-20 | Incyte Corporation | Substituted heterocycles as Janus kinase inhibitors |
ES2546816T3 (es) * | 2007-02-27 | 2015-09-28 | Nerviano Medical Sciences S.R.L. | Isoquinolinpirrolopiridinonas activas como inhibidores de cinasa |
CL2008001709A1 (es) | 2007-06-13 | 2008-11-03 | Incyte Corp | Compuestos derivados de pirrolo [2,3-b]pirimidina, moduladores de quinasas jak; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como cancer, psoriasis, artritis reumatoide, entre otras. |
RS58449B1 (sr) | 2007-06-13 | 2019-04-30 | Incyte Holdings Corp | Upotreba soli inhibitora janus kinaze (r)-3-(4-(7h-pirolo[2,3-d]pirimidin-4-il)-1h- pirazol-1-il)-3-ciklopentilpropionitrila |
JO3259B1 (ar) | 2008-02-26 | 2018-09-16 | Takeda Pharmaceuticals Co | مشتق دائري مغاير ملتحم واستخدامه |
TWI444382B (zh) | 2008-03-11 | 2014-07-11 | Incyte Corp | 作為jak抑制劑之氮雜環丁烷及環丁烷衍生物 |
EP3643312A1 (en) | 2009-05-22 | 2020-04-29 | Incyte Holdings Corporation | 3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl]octane- or heptane-nitrile as jak inhibitors |
AU2010249380B2 (en) | 2009-05-22 | 2015-08-20 | Incyte Holdings Corporation | N-(hetero)aryl-pyrrolidine derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines and pyrrol-3-yl-pyrrolo[2,3-d]pyrimidines as Janus kinase inhibitors |
AR078012A1 (es) | 2009-09-01 | 2011-10-05 | Incyte Corp | Derivados heterociclicos de las pirazol-4-il- pirrolo (2,3-d) pirimidinas como inhibidores de la quinasa janus |
KR20180126619A (ko) | 2009-10-09 | 2018-11-27 | 인사이트 홀딩스 코포레이션 | 3-(4-(7H-피롤로〔2,3-d〕피리미딘-4-일)-1H-피라졸-1-일)-3-사이클로펜틸프로판니트릴의 하이드록실, 케토 및 글루쿠로나이드 유도체 |
AU2014277711B2 (en) * | 2009-12-14 | 2016-10-27 | Merck Sharp & Dohme B.V. | MK2 inhibitors |
EP2513111B1 (en) * | 2009-12-14 | 2013-10-02 | Merck Sharp & Dohme B.V. | Mk2 inhibitors |
CN102985417B (zh) | 2010-03-10 | 2015-01-28 | 因塞特公司 | 作为jak1抑制剂的哌啶-4-基氮杂环丁烷衍生物 |
EA035981B1 (ru) | 2010-05-21 | 2020-09-09 | Инсайт Холдингс Корпорейшн | Композиция ингибитора jak для местного применения |
EP2640725B1 (en) | 2010-11-19 | 2015-01-07 | Incyte Corporation | Heterocyclic-substituted pyrrolopyridines and pyrrolopyrimidines as jak inhibitors |
TW201249845A (en) | 2010-11-19 | 2012-12-16 | Incyte Corp | Cyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as JAK inhibitors |
EP2675451B9 (en) | 2011-02-18 | 2017-07-26 | Novartis Pharma AG | mTOR/JAK INHIBITOR COMBINATION THERAPY |
USRE48140E1 (en) | 2011-03-31 | 2020-08-04 | Carna Biosciences, Inc. | Furanone derivative |
WO2012177606A1 (en) | 2011-06-20 | 2012-12-27 | Incyte Corporation | Azetidinyl phenyl, pyridyl or pyrazinyl carboxamide derivatives as jak inhibitors |
US9358229B2 (en) | 2011-08-10 | 2016-06-07 | Novartis Pharma Ag | JAK PI3K/mTOR combination therapy |
TW201313721A (zh) | 2011-08-18 | 2013-04-01 | Incyte Corp | 作為jak抑制劑之環己基氮雜環丁烷衍生物 |
UA111854C2 (uk) | 2011-09-07 | 2016-06-24 | Інсайт Холдінгс Корпорейшн | Способи і проміжні сполуки для отримання інгібіторів jak |
TW201406761A (zh) | 2012-05-18 | 2014-02-16 | Incyte Corp | 做爲jak抑制劑之哌啶基環丁基取代之吡咯并吡啶及吡咯并嘧啶衍生物 |
US9604980B2 (en) | 2012-11-07 | 2017-03-28 | Nerviano Medical Sciences S.R.L. | Substituted pyrimidinyl and pyridinyl-pyrrolopyridinones, process for their preparation and their use as kinase inhibitors |
CN113384545A (zh) | 2012-11-15 | 2021-09-14 | 因赛特公司 | 鲁索利替尼的缓释剂型 |
SI3489239T1 (sl) | 2013-03-06 | 2022-04-29 | Incyte Holdings Corporation | Postopki in intermediati za pripravo zaviralca JAK |
EA201690357A1 (ru) | 2013-08-07 | 2016-07-29 | Инсайт Корпорейшн | Лекарственные формы с замедленным высвобождением для ингибитора jak1 |
EP3100742B1 (en) | 2014-01-31 | 2020-05-20 | Carna Biosciences Inc. | Anticancer agent composition comprising a cdc7 inhibitor and a wee1 inhibitor |
US9498467B2 (en) | 2014-05-30 | 2016-11-22 | Incyte Corporation | Treatment of chronic neutrophilic leukemia (CNL) and atypical chronic myeloid leukemia (aCML) by inhibitors of JAK1 |
US10596161B2 (en) | 2017-12-08 | 2020-03-24 | Incyte Corporation | Low dose combination therapy for treatment of myeloproliferative neoplasms |
SI3746429T1 (sl) | 2018-01-30 | 2023-01-31 | Incyte Corporation | Postopki za pripravo (1-(3-fluoro-2-(trifluorometil)izonikotinil) piperidin-4-ona) |
WO2019191684A1 (en) | 2018-03-30 | 2019-10-03 | Incyte Corporation | Treatment of hidradenitis suppurativa using jak inhibitors |
CA3128946A1 (en) * | 2019-02-07 | 2020-08-13 | Bayer Aktiengesellschaft | 3-amino-2-[2-(acylamino)pyridin-4-yl]-1,5,6,7-tetrahydro-4h-pyrrolo[3,2-c]pyridin-4-one as csnk1 inhibitors |
EP4061367A1 (en) | 2019-11-22 | 2022-09-28 | Incyte Corporation | Combination therapy comprising an alk2 inhibitor and a jak2 inhibitor |
US11833155B2 (en) | 2020-06-03 | 2023-12-05 | Incyte Corporation | Combination therapy for treatment of myeloproliferative neoplasms |
CN115322192B (zh) * | 2022-08-15 | 2023-07-14 | 重庆文理学院 | 吡咯并[3,4-b]吡啶类衍生物及其合成方法与应用 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0912548A1 (en) * | 1996-07-11 | 1999-05-06 | Pfizer Inc. | Pyridylpyrrole compounds useful as interleukin- and tnf antagonists |
US6420382B2 (en) * | 2000-02-25 | 2002-07-16 | Merck & Co., Inc. | Tyrosine kinase inhibitors |
HU229824B1 (en) * | 2000-08-10 | 2014-08-28 | Pfizer Italia Srl | Bicyclo-pyrazoles active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them |
ES2252524T3 (es) * | 2001-09-24 | 2006-05-16 | Bayer Pharmaceuticals Corporation | Preparacion y uso de derivados de 1,5,6,7-tetrahidropirrolo(3,2-c)piridina para el tratamiento de la obesidad. |
ZA200504898B (en) * | 2002-12-20 | 2006-11-29 | Pharmacia Corp | Acyclic pyrazole compounds |
-
2004
- 2004-08-05 US US10/912,323 patent/US20050043346A1/en not_active Abandoned
- 2004-08-06 JP JP2006522963A patent/JP2007501825A/ja not_active Abandoned
- 2004-08-06 MX MXPA06001557A patent/MXPA06001557A/es not_active Application Discontinuation
- 2004-08-06 DE DE602004017194T patent/DE602004017194D1/de not_active Expired - Fee Related
- 2004-08-06 EP EP04763848A patent/EP1660085B1/en not_active Not-in-force
- 2004-08-06 BR BRPI0413427-3A patent/BRPI0413427A/pt not_active IP Right Cessation
- 2004-08-06 WO PCT/EP2004/008811 patent/WO2005013986A1/en active Search and Examination
- 2004-08-06 AT AT04763848T patent/ATE411022T1/de not_active IP Right Cessation
- 2004-08-06 CA CA002535125A patent/CA2535125A1/en not_active Abandoned
- 2004-08-06 ES ES04763848T patent/ES2313051T3/es active Active
Also Published As
Publication number | Publication date |
---|---|
MXPA06001557A (es) | 2006-05-15 |
ATE411022T1 (de) | 2008-10-15 |
WO2005013986A1 (en) | 2005-02-17 |
CA2535125A1 (en) | 2005-02-17 |
DE602004017194D1 (de) | 2008-11-27 |
EP1660085B1 (en) | 2008-10-15 |
JP2007501825A (ja) | 2007-02-01 |
EP1660085A1 (en) | 2006-05-31 |
US20050043346A1 (en) | 2005-02-24 |
ES2313051T3 (es) | 2009-03-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BRPI0413427A (pt) | derivados de piridilpirrol ativos como inibidores da cinase | |
MXPA06000302A (es) | Derivados de pirazolil-indol activos como inhibidores de cinasa, procedimientos para su preparacion y composiciones farmaceuticas que los comprenden. | |
DK1636236T3 (da) | Pyrazolo-quinazolin-derivater, en fremgangsmåde til fremstilling deraf, og deres anvendelse som kinase-inhibitorer | |
ATE557015T1 (de) | 3,4-diarylpyrazole als proteinkinaseinhibitoren | |
HK1136292A1 (en) | Substituted pyrazolo-quinazoline derivatives, process for their preparation and their use as kinase inhibitors | |
EA200970595A1 (ru) | Производные замещенных индазолов, активные в качестве ингибиторов киназ | |
ATE514699T1 (de) | Substituierte pyrrolopyrazolderivate als kinaseinhibitoren | |
BRPI0413438A (pt) | derivados de pirimidilpirrol ativos como inibidores de cinase | |
UA99141C2 (ru) | Замещенные производные индазола, активные в качестве ингибиторов киназы | |
WO2009071480A3 (en) | Substituted dihydropteridin-6-one derivatives, process for their preparation and their use as kinase inhibitors | |
TW200510385A (en) | Pyrrolo[3, 4-c]pyrazole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them | |
NO20061506L (no) | Heterocykliske inhibitorer av MEK og fremgangsmater for anvendelse derav | |
GT200500020A (es) | Derivados de 1h-tieno[2,3-c]pirazol utiles como inhibidores de quinasa. | |
NO20055891L (no) | Kinazolinderivater som aurorakinaseinhibitorer | |
UA102219C2 (ru) | Замещенные пиразолохиназолиновые производные, способ их получения и их применения как ингибиторов киназы | |
CU23566B7 (es) | Derivados de pirrolo [3,4-c]pirazol activos como inhibidores de quinasa |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE AS 5A, 6A E 7A ANUIDADES. |
|
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2159 DE 22/05/2012. |